... to in the content or advertisements. Antineutrophil cytoplasmic antibody Mycophenolate mofetil Mycophenolic acid Toxicity Vasculitis The introduction of cyclophosphamide and glucocorticoids dramatically changed the prognosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides...

... of mycophenolate mofetil (MMF) in high-risk patients with primary GN. Methods: A total of 51 patients with biopsy-proven membranous (n = 12), membranoproliferative (n = 15), mesangioproliferative (n = 10), focal segmental glomerulosclerosis (n = 13) and minimal change disease (n = 1) received MMF with low-dose...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Post-transplantation anaemia Risk factors, renal transplantation Immunosuppression Azathioprine Mycophenolate mofetil...

...Maria Koukoulaki; David R.W. Jayne Background: Mycophenolate mofetil (MMF) is an immune suppressive initially introduced for the prevention of solid organ allograft rejection that is increasingly used in autoimmune conditions, including vasculitis. Methods: This retrospective study evaluated...

...Jane Cross; Adu Dwomoa; Peter Andrews; Aine Burns; Caroline Gordon; John Main; Peter Mathieson; Donal O’Donoghue; David Jayne Background: Mycophenolate mofetil (MMF) is a potential alternative immunosuppressive to cyclophosphamide or azathioprine for the treatment of lupus nephritis. It has...

... reports have demonstrated that mycophenolate mofetil (MMF) is effective in treating native kidney glomerular disease. The effects of MMF are dose related. Therefore, we hypothesized that high-dose MMF (3 g/day) would be effective in treating glomerular disease in the allograft, minimizing the need...